Combining Molecularly Targeted Agents: Is More Always Better?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 27836864.
- Also identified by DOI 10.1158/1078-0432.CCR-16-2399.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The concurrent targeting of critical nodes along key signaling pathways with molecularly targeted agents is a rational antitumor strategy, which has had varying degrees of success. Combinatorial challenges include overcoming synergistic toxicities and establishing whether combinations are truly active, to make "go, no-go" decisions to proceed to later phase trials. <i>Clin Cancer Res; 23(5); 1123-5. ©2016 AACR</i><i>See related article by Calvo et al., p. 1177</i>.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Molecular Targeted Therapy
- Neoplasms